Using RYZ811 and RYZ801 to identify and treat patients with advanced liver cancer
Phase 1/2 Randomized, Controlled, Open-label Trial of Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ Unresectable Hepatocellular Carcinoma (HCC)
This study is testing a new way to find and treat people with advanced liver cancer using two agents, RYZ811 for diagnosis and RYZ801 for treatment, to see how well they work together.
Quick facts
| Phase | Phase1; Phase2 |
|---|---|
| Study type | Interventional |
| Enrollment | 590 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | RayzeBio, Inc. Industry-sponsored |
| Drugs / interventions | lenvatinib |
| Locations | 13 sites (Birmingham, Alabama and 12 other locations) |
| Trial ID | NCT06726161 on ClinicalTrials.gov |
What this trial studies
This Phase 1 interventional study evaluates the theranostic pair RYZ811, a diagnostic agent, and RYZ801, a therapeutic agent, in patients with GPC3+ unresectable hepatocellular carcinoma (HCC). The study aims to identify suitable candidates for treatment and assess the safety and efficacy of these agents. Participants will be monitored for measurable disease progression and response to the therapy. The study is designed to provide insights into the potential benefits of this novel approach in managing advanced liver cancer.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older with histologically confirmed unresectable HCC and specific eligibility criteria.
Not a fit: Patients with resectable HCC or those who do not meet the inclusion criteria, such as poor liver function or significant comorbidities, may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a targeted treatment option for patients with advanced liver cancer that is currently difficult to treat.
How similar studies have performed: While this approach is novel, similar theranostic strategies have shown promise in other studies, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age of at least 18 years at the time of signing the informed consent form (ICF) * Histologically/cytologically confirmed diagnosis of HCC. * Barcelona Clinic Liver Cancer (BCLC) Stage C or BCLC Stage B not amenable to locoregional therapy * Child-Pugh A * Eastern Cooperative Oncology Group (ECOG) performance status (PS 0-1) * Disease progression after 1 prior systemic therapy for unresectable HCC * Measurable disease per RECIST v1.1 * Sufficient renal function * Adequate hematologic function * Adequate hepatic function * The subject must have recovered from toxicities related to prior treatments to ≤Grade 1, unless clinically nonsignificant and/or stable on supportive therapy * If HBV or HCV infection: Disease managed per local practice; antiviral treatment is allowed. * Gastric or esophageal varices previously treated with endoscopic therapy according to institutional standards are permitted if no clinically significant bleeding * For women of childbearing potential (WOCBP): * Negative serum pregnancy test within 48 hours prior to the first dose of RYZ811 * Agreement to use barrier contraception and a second form of highly effective contraception * For sexually active males: * Must use a condom during intercourse * Male subjects whose sexual partners are WOCBP must also agree to use a second form of highly effective contraception * A condom is required to be used also by vasectomized men Exclusion Criteria: * Subjects with fibrolamellar carcinoma, sarcomatoid HCC or combined hepatocellular cholangiocarcinoma * Prior liver transplantation * Known hypersensitivity to 68Ga, 225Ac or any of the excipients of RYZ811 or RYZ801 * Portal vein tumor thrombosis classified as Vp4 * Documented hepatic encephalopathy within 6 months of enrollment * Clinically meaningful ascites within 6 months of enrollment * Prior EBRT to the liver within 12 weeks prior to receiving RYZ811 * Prior liver radioembolization * Previously treated central nervous system (CNS) metastasis without recovery from acute side effects * Documented history of idiopathic pulmonary fibrosis (IPF), interstitial lung disease (ILD) or pneumonitis * Uncontrolled significant intercurrent illness including, but not limited to: * QT interval corrected for heart rate using Fridericia's formula (QTcF) \>470 ms * Hemoglobin A1c (Hgb A1c) ≥8% * Uncontrolled hypertension * Dose Expansion only: Prior treatment with lenvatinib is exclusionary * Significant cardiovascular disease or heart failure * History of clinically significant bleeding * Prior participation in any interventional clinical study * Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study * Have a history of primary malignancy within the past 3 years other than (1) HCC, (2) adequately treated carcinoma in situ or non-melanoma carcinoma of the skin, (3) any other curatively treated malignancy that is not expected to require treatment for recurrence during participation in the study, or (4) an untreated cancer on active surveillance that may not affect the subject's survival status for \>3 years * Subject requires other treatment that in the opinion of the Investigator would be more appropriate than what is offered in the study * Pregnancy or breastfeeding Note: Additional criteria may apply and will be assessed by the study site
Where this trial is running
Birmingham, Alabama and 12 other locations
- Research Facility — Birmingham, Alabama, United States (Recruiting)
- Research Facility — Phoenix, Arizona, United States (Recruiting)
- Research Facility — Tucson, Arizona, United States (Recruiting)
- Research Facility — Orange, California, United States (Recruiting)
- Research Facility — Jacksonville, Florida, United States (Recruiting)
- Research Facility — Lexington, Kentucky, United States (Recruiting)
- Research Facility — Baltimore, Maryland, United States (Recruiting)
- Research Facility — Rochester, Minnesota, United States (Recruiting)
- Research Facility — Omaha, Nebraska, United States (Recruiting)
- Research Facility — New York, New York, United States (Recruiting)
- Research Facility — Houston, Texas, United States (Recruiting)
- Research Facility — Charlottesville, Virginia, United States (Recruiting)
- Research Facility — Seattle, Washington, United States (Recruiting)
Study contacts
- Study coordinator: RayzeBio Clinical Trials
- Email: clinicaltrials@rayzebio.com
- Phone: 1-619-657-0057
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.